Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 3 · below the Ichimoku cloud · RSI 24 (oversold) · MACD below its signal · 6% above its 52-week low
| 15.50 | 52-week high | +2802.08% |
| 2.67 | Previous month high | +399.91% |
| 1.32 | Previous month low | +147.14% |
| 0.7510 | Previous week high | +40.61% |
| 0.6037 | R3 (classic) | +13.03% |
| 0.5773 | R2 (classic) | +8.09% |
| 0.5557 | R1 (classic) | +4.04% |
| 0.5510 | Previous day high | +3.16% |
| 0.5450 | Previous week low | +2.04% |
| 0.5341 | Price now | |
| 0.5293 | Pivot | −0.89% |
| 0.5077 | S1 (classic) | −4.95% |
| 0.5030 | Previous day low | −5.82% |
| 0.5030 | 52-week low | −5.82% |
| 0.4813 | S2 (classic) | −9.88% |
| 0.4597 | S3 (classic) | −13.94% |
None of the 29 investors followed here reported a position in SCNI in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a SCNI trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 15, 2026 | Germain Mark SDirector | Stock Award(Grant) at price 0.00 per share. | 120.00M | — |
| Jun 15, 2026 | Reichman AmirChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 400.00M | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 37.6 | -9.3 | -35.9 | 29.8 | -39.2 | -43.8 | 7.9 | -8.4 | -43.2 | -62.4 | −92.5% | ||
| 2025 | 7.3 | -1.4 | -23.9 | -2.1 | 3.1 | -16.2 | -36.0 | 4.8 | -17.3 | 10.7 | -26.4 | -30.9 | −78.7% |
| 2024 | -20.8 | 4.2 | 5.7 | -12.3 | -17.6 | -25.9 | 67.6 | -20.0 | -7.5 | 3.2 | -3.4 | -2.8 | −43.8% |
| 2023 | -11.8 | -9.8 | -8.3 | -10.6 | -8.3 | -20.3 | -5.7 | 1.5 | -35.6 | -24.1 | 8.9 | -17.2 | −79.9% |
| 2022 | -44.3 | -3.1 | 30.7 | -22.3 | 3.9 | -13.1 | 2.6 | -7.5 | -33.9 | 4.0 | 28.6 | -69.7 | −87.4% |
| 2021 | 61.9 | -12.5 | -4.5 | -15.8 | -5.3 | -5.3 | 1.7 | -7.9 | -18.2 | -5.5 | -17.3 | 36.6 | −16.4% |
| 2020 | 17.8 | -25.2 | -5.9 | 75.3 | 47.4 | 14.3 | 50.5 | 9.5 | 4.3 | -92.3 | 8.7 | -13.8 | −69.8% |
| 2019 | 10.7 | -8.5 | 12.4 | 32.4 | -7.6 | -13.3 | 16.5 | -12.1 | 0.9 | -8.5 | 6.0 | 60.8 | +94.8% |
| 2018 | 35.4 | -17.4 | -9.4 | 11.4 | 6.0 | 4.1 | -11.5 | -3.1 | -2.0 | -4.5 | 10.3 | -19.2 | −11.0% |
| 2017 | 50.7 | 18.8 | -3.3 | 12.9 | 13.0 | 18.7 | 8.4 | -16.3 | -10.3 | 2.1 | -20.3 | -7.9 | +60.0% |
| 2016 | -9.1 | 12.5 | -7.9 | 6.2 | -9.1 | -2.8 | -5.4 | 17.2 | -5.2 | 6.0 | -5.6 | -9.0 | −15.4% |
| 2015 | 13.8 | -14.1 | -17.6 | 4.9 | 6.0 | -1.2 | 3.1 | −9.0% |
TimeframesThe daily, weekly and monthly trends are down; the hourly is steadying, a bounce inside them.
bouncing over the 21 EMA
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
No analyst coverage for this instrument.
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.